Reference | </br>1:Comparison of the Safety and Efficacy of Loteprednol Etabonate 0.5%/Tobramycin 0.3% with Dexamethasone 0.1%/Tobramycin 0.3% Following Strabismus Surgery. Salman İA.Eurasian J Med. 2016 Oct;48(3):186-188. doi: 10.5152/eurasianjmed.2016.0264. PMID: 28149143 Free PMC Article</br>2:Dose Uniformity of Topical Corticosteroids: A Simulated Trial of Fluorometholone Acetate 0.1% and Loteprednol Etabonate Gel 0.5. Stevens CE, Bennion JL, Caldwell MC, Townley JR, Apsey DA, Schwertner HA.J Ocul Pharmacol Ther. 2017 Mar;33(2):111-114. doi: 10.1089/jop.2016.0151. Epub 2017 Jan 31. PMID: 28140772 </br>3:Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. Liu RF, Wu XX, Wang X, Gao J, Zhou J, Zhao Q.Int Forum Allergy Rhinol. 2017 Apr;7(4):393-398. doi: 10.1002/alr.21882. Epub 2016 Nov 21. PMID: 27869354 Free PMC Article</br>4:Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Patel N, Nakrani H, Raval M, Sheth N.Drug Deliv. 2016 Nov;23(9):3712-3723. Epub 2016 Sep 30. PMID: 27689408 </br>5:Loteprednol Etabonate Nanoparticles: Optimization via Box-Behnken Design Response Surface Methodology and Physicochemical Characterization. Sah AK, Suresh PK.Curr Drug Deliv. 2016 Aug 1. [Epub ahead of print] PMID: 27480117 </br>6:Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate. Soliman OAE, Mohamed EAM, El-Dahan MS, Khatera NAA.AAPS PharmSciTech. 2017 May;18(4):1228-1241. doi: 10.1208/s12249-016-0589-9. Epub 2016 Jul 28. PMID: 27469220 </br>7:PLGA nanoparticles for ocular delivery of loteprednol etabonate: a corneal penetration study. Sah AK, Suresh PK, Verma VK.Artif Cells Nanomed Biotechnol. 2016 Jul 8:1-9. doi: 10.1080/21691401.2016.1203794. [Epub ahead of print] PMID: 27389068 </br>8:Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Sheppard JD, Comstock TL, Cavet ME.Adv Ther. 2016 Apr;33(4):532-52. doi: 10.1007/s12325-016-0315-8. Epub 2016 Mar 17. Review. PMID: 26984315 Free PMC Article</br>9:Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis. Comstock TL, DeCory HH.Ocul Immunol Inflamm. 2017 Apr;25(2):267-274. doi: 10.3109/09273948.2015.1115879. Epub 2016 Jan 20. PMID: 26788833 </br>10:A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Salinger CL, Gordon M, Jackson MA, Perl T, Donnenfeld E.Clin Ophthalmol. 2015 Nov 6;9:2089-97. doi: 10.2147/OPTH.S94332. eCollection 2015. PMID: 26609219 Free PMC Article
|